About | Free Trial

Last Update

2015-12-06T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Andrew Mazar?

Dr. Andrew Mazar P. PhD

Consulting Head of Product Development

Lung Therapeutics, Inc.

Lung Therapeutics, Inc.

Background Information

Employment History

Development Consultant
Wilson Therapeutics

Chief Scientific Officer
Attenuon , LLC

Affiliations

Member of Study Sections
National Institutes of Health

Managing Member and Consulting Chief Scientific Officer
Tactic Pharma LLC

Founder
Tactic Pharmaceuticals

Education

Ph.D.
Biochemistry
University of Illinois College of Medicine

Web References (48 Total References)


Team | Lung Therapeutics, Inc.

www.lungtx.com [cached]

Andrew Mazar, Ph.D.

Founder and Head of Product Development
Research


Press Room | Lung Therapeutics, Inc.

www.lungtx.com [cached]

Andrew Mazar, Ph.D. Biography

Founder and Head of Product Development
Recent News
...
Andrew Mazar, Ph.D.
Research


Home > Andrew Mazar, ...

www.lungtx.com [cached]

Home > Andrew Mazar, Ph.D.

...
Andrew Mazar, Ph.D.
...
Andrew Mazar, Ph.D.
Founder and Head of Product Development
Dr. Mazar serves as Head of Product Development in addition to his current position as Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence at Northwestern University. Prior to this, Dr. Mazar was most recently the Chief Scientific Officer at Attenuon, LLC and has led three projects at Attenuon through IND and into phase II trials. He is currently managing an additional three projects at various stages of IND enabling development. Prior to Attenuon, Dr. Mazar had significant input in three projects that led two successful INDs, two of which made it through phase II trials and one of which is currently in phase II trials. One of these projects was the original development of scuPA for the treatment of myocardial infarction. Thus, Dr. Mazar has extensive expertise in translating early stage science into clinical projects through phase II clinical development and managing this entire process. He also has direct experience in the development of LTI-01 (scuPA) as a clinical therapeutic agent.
During his tenure in biotechnology, Dr. Mazar has led several projects that culminated in several out-license deals as well as funded collaborations. A new partnership deal with a large European venture group on all of Attenuon's projects has closed. During the partnership process, Dr. Mazar led early and late stage discussion with most every large and mid-size biotechnology company interested in cancer therapeutics. During these discussions, terms sheets were obtained from five different suitors, all of them public companies. While at Attenuon, Dr. Mazar managed $63M of investment capital, the majority of this raised through a single investor, during his nine year tenure and led a road show managed by Bank of America.


About Us | Panther Biotechnology, Inc.

pantherbiotechnology.com [cached]

Andrew P. Mazar Ph.D. (Consulting VP of R&D): Dr. Mazar is a twenty year veteran of oncology drug discovery and development. He is internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis. He led R&D at two start-up companies in San Diego and has been responsible for advancing numerous drug candidates from discovery through mid-stage clinical trials. Dr. Mazar is an Associate Editor for Recent Patent Reviews on Anti - Cancer Drug Discovery and a member of the editorial board of Clinical Cancer Research. He has served on study sections for the NIDDK, NHLBI, NIH Special Emphasis Panels, VA Oncology Merit Review, AHA and the Phillip Morris External Research Program. Dr. Mazar is a reviewer for numerous journals and is the co-author of 98 peer reviewed publications.


Andrew P. Mazar, ...

www.monopartherapeutics.com [cached]

Andrew P. Mazar, PhD

Co-Founder and Chief Scientific Officer
Dr. Mazar has spent twenty five years working on drug discovery and development at the interface of academia and industry and has founded or co-founded eight start-up companies to commercialize new drug discoveries. He is also internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis as well as basic mechanisms of cancer metastasis. He is the co-author of 99 peer reviewed publications and 16 reviews and book chapters. Prior to co-founding Tactic Pharmaceuticals in 2010 and joining the Chemistry of Life Processes Institute at Northwestern University in 2009, Dr. Mazar was the Chief Scientific Officer at Attenuon, LLC in San Diego from 2000 to 2009 and led discovery and development efforts resulting in three drugs entering oncology clinical trials. Dr. Mazar has now overseen 11 IND enabling efforts, many of these focused on drugs discovered in academia.

Similar Profiles

Other People with this Name

Other people with the name Mazar

Jessie Mazar
Vermont Community Garden Network

Adrian Mazar

Petar Mazar
Cipla Ltd.

Michael Mazar
Trican

Miroslav Mazar
Molson Coors Brewing Company

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory